Immutep Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IMMP?
Source: Globenewswire
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, highlighting the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.442
Low
12.00
Averages
12.00
High
12.00
Current: 0.442
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, highlighting the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could impact the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to halt the TACTI-004 Phase III trial, resulting in a major setback for the company’s R&D efforts and potentially affecting future product launch plans.
- Stock Price Plunge: Following the trial discontinuation news, Immutep's American Depositary Receipt (ADR) price fell by $2.27, or 82.44%, closing at $0.48, reflecting the market's pessimistic outlook on the company's future prospects.
- Legal Firm Background: Pomerantz LLP, a leading firm in securities class action litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud, and this lawsuit may prompt increased scrutiny of Immutep's compliance and governance practices.
See More
Immutep Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has launched a class action against Immutep Limited on behalf of investors who purchased securities between March 24, 2025, and March 12, 2026, requiring investors to file a lead plaintiff motion by July 6, 2026, highlighting the firm's commitment to investor rights.
- Basis for Lawsuit: The lawsuit alleges that Immutep concealed the true performance of efti in the TACTI-004 Phase III trial, despite positive efficacy and safety results from other trials, leading investors to make decisions based on misleading information, which adversely affected the company's reputation and stock price.
- Stock Price Plunge: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 trial based on the Independent Data Monitoring Committee's recommendation, resulting in a more than 82% drop in the company's ADR price, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Support Offered: The Portnoy Law Firm provides complimentary case evaluations and encourages investors to reach out for assistance in recovering losses, demonstrating a strong commitment to supporting affected investors and offering legal recourse.
See More
Immutep Accused of Misleading Investors in Class Action
- Class Action Filed: Robbins LLP reminds all investors who purchased Immutep Limited American Depository Receipts between March 24, 2025, and March 12, 2026, that a class action has been initiated, accusing the company of misleading investors regarding the efficacy and viability of its drug candidate.
- Clinical Trial Issues: The complaint alleges that Immutep concealed critical data regarding the TACTI-004 trial, as despite positive efficacy and safety results in other trials, internal data indicated that the study was at risk of failing to meet its primary efficacy and safety endpoints.
- Stock Price Plummet: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to futility, causing its ADR price to plummet from $2.76 to $0.48, a staggering decline of approximately 83%, severely impacting investor confidence.
- Investor Rights Protection: Investors are eligible to submit papers to become lead plaintiffs in the class action by July 6, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders can recover losses without upfront costs or risks associated with litigation.
See More
Faruqi & Faruqi Investigates Immutep Securities Litigation
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Immutep (NASDAQ: IMMP), particularly for investors who purchased securities between March 24, 2025, and March 12, 2026, urging them to seek lead plaintiff status by the July 6, 2026 deadline, indicating significant legal risks for the company.
- Clinical Trial Failure: Immutep faced a major setback in its TACTI-004 Phase III clinical trial, with the Independent Data Monitoring Committee recommending trial discontinuation due to failure to meet primary efficacy and safety endpoints, resulting in an 82.6% drop in stock price on March 13, 2026, causing substantial financial losses for investors.
- False Statement Allegations: The lawsuit alleges that Immutep and its executives violated federal securities laws by making false or misleading statements regarding the TACTI-004 trial, concealing material adverse facts that could mislead investors about the company's prospects.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Immutep's conduct, including whistleblowers and former employees, to come forward to provide legal support for affected investors, ensuring their rights are protected.
See More
Immutep Faces Class Action Lawsuit, Stock Price Plummets
- Class Action Filed: A securities class action lawsuit has been initiated in the Southern District of New York against Immutep, covering all investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, highlighting significant investor concern over the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that defendants provided positive statements while concealing critical adverse facts regarding the efficacy and safety of the TACTI-004 Phase III clinical trial, potentially misleading investors into making uninformed decisions.
- Trial Discontinuation Impact: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to a planned interim futility analysis, leading to a collapse in investor confidence.
- Stock Price Collapse: Following the announcement, Immutep's ADR price plummeted from $2.76 per share on March 12, 2026, to $0.48 per share on March 13, 2026, marking an approximately 83% decline, reflecting extreme pessimism regarding the company's future prospects.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, to participate.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: When the market learned the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, highlighting the firm's focus on securities class action lawsuits aimed at helping investors recover losses.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could impact the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to halt the TACTI-004 Phase III trial, resulting in a major setback for the company’s R&D efforts and potentially affecting future product launch plans.
- Stock Price Plunge: Following the trial discontinuation news, Immutep's American Depositary Receipt (ADR) price fell by $2.27, or 82.44%, closing at $0.48, reflecting the market's pessimistic outlook on the company's future prospects.
- Legal Firm Background: Pomerantz LLP, a leading firm in securities class action litigation with over 85 years of experience, focuses on fighting for the rights of victims of securities fraud, and this lawsuit may prompt increased scrutiny of Immutep's compliance and governance practices.
See More
Immutep Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has launched a class action against Immutep Limited on behalf of investors who purchased securities between March 24, 2025, and March 12, 2026, requiring investors to file a lead plaintiff motion by July 6, 2026, highlighting the firm's commitment to investor rights.
- Basis for Lawsuit: The lawsuit alleges that Immutep concealed the true performance of efti in the TACTI-004 Phase III trial, despite positive efficacy and safety results from other trials, leading investors to make decisions based on misleading information, which adversely affected the company's reputation and stock price.
- Stock Price Plunge: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 trial based on the Independent Data Monitoring Committee's recommendation, resulting in a more than 82% drop in the company's ADR price, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Support Offered: The Portnoy Law Firm provides complimentary case evaluations and encourages investors to reach out for assistance in recovering losses, demonstrating a strong commitment to supporting affected investors and offering legal recourse.
See More
Immutep Accused of Misleading Investors in Class Action
- Class Action Filed: Robbins LLP reminds all investors who purchased Immutep Limited American Depository Receipts between March 24, 2025, and March 12, 2026, that a class action has been initiated, accusing the company of misleading investors regarding the efficacy and viability of its drug candidate.
- Clinical Trial Issues: The complaint alleges that Immutep concealed critical data regarding the TACTI-004 trial, as despite positive efficacy and safety results in other trials, internal data indicated that the study was at risk of failing to meet its primary efficacy and safety endpoints.
- Stock Price Plummet: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to futility, causing its ADR price to plummet from $2.76 to $0.48, a staggering decline of approximately 83%, severely impacting investor confidence.
- Investor Rights Protection: Investors are eligible to submit papers to become lead plaintiffs in the class action by July 6, 2026, with Robbins LLP offering contingency fee representation, ensuring shareholders can recover losses without upfront costs or risks associated with litigation.
See More
Faruqi & Faruqi Investigates Immutep Securities Litigation
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Immutep (NASDAQ: IMMP), particularly for investors who purchased securities between March 24, 2025, and March 12, 2026, urging them to seek lead plaintiff status by the July 6, 2026 deadline, indicating significant legal risks for the company.
- Clinical Trial Failure: Immutep faced a major setback in its TACTI-004 Phase III clinical trial, with the Independent Data Monitoring Committee recommending trial discontinuation due to failure to meet primary efficacy and safety endpoints, resulting in an 82.6% drop in stock price on March 13, 2026, causing substantial financial losses for investors.
- False Statement Allegations: The lawsuit alleges that Immutep and its executives violated federal securities laws by making false or misleading statements regarding the TACTI-004 trial, concealing material adverse facts that could mislead investors about the company's prospects.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Immutep's conduct, including whistleblowers and former employees, to come forward to provide legal support for affected investors, ensuring their rights are protected.
See More
Immutep Faces Class Action Lawsuit, Stock Price Plummets
- Class Action Filed: A securities class action lawsuit has been initiated in the Southern District of New York against Immutep, covering all investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, highlighting significant investor concern over the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that defendants provided positive statements while concealing critical adverse facts regarding the efficacy and safety of the TACTI-004 Phase III clinical trial, potentially misleading investors into making uninformed decisions.
- Trial Discontinuation Impact: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to a planned interim futility analysis, leading to a collapse in investor confidence.
- Stock Price Collapse: Following the announcement, Immutep's ADR price plummeted from $2.76 per share on March 12, 2026, to $0.48 per share on March 13, 2026, marking an approximately 83% decline, reflecting extreme pessimism regarding the company's future prospects.
See More
